PTCT, US69366J2006

PTC Therapeutics schedules October 29 results as stock trades below its high

Published on 10/20/2026 at 18:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

PTC Therapeutics reports third-quarter results on October 29, 2026. PTC Therapeutics stock costs EUR 55.60 on October 20, 2026.

Reporting date October 29, 2026

PTC Therapeutics will report third-quarter 2026 results on October 29, 2026.
Second-quarter 2026 revenue reached USD 360.52 million, up 101.50 percent year over year.
PTC Therapeutics stock was trading at EUR 55.60 at Lang & Schwarz on October 20, 2026 at 6:44 p.m. CEST.
Truist Financial assigned a USD 62.00 target and a Hold rating on October 16, 2026.

PTCT, US69366J2006, Illustration mit AI erstellt.

PTC Therapeutics, Inc. (ISIN US69366J2006) is scheduled to report its third-quarter 2026 financial results on October 29, 2026. The company will host a conference call at 4:30 p.m. ET, according to PTC Therapeutics. The stock was trading at EUR 55.60 at Lang & Schwarz on October 20, 2026 at 6:44 p.m. CEST.

Revenue doubled in the second quarter

PTC Therapeutics reported USD 360.52 million in revenue for the second quarter of 2026, an increase of 101.50 percent from the same quarter of 2025. Net income reached USD 83.50 million, compared with a net loss in the prior-year quarter, while profit margin was 23.16 percent, according to Simply Wall St.

The second-quarter performance gives the October 29 report a clear comparison point. The company had reported adjusted earnings per share of USD 0.92 for that period against a consensus estimate of USD 0.24, while revenue exceeded the USD 298.63 million estimate.

What does the analyst view imply?

Truist Financial resumed coverage of PTC Therapeutics with a Hold rating and a USD 62.00 price target on October 16, 2026, according to GuruFocus. The report cited concerns about long-term growth and the addressable market for Sephience in phenylketonuria.

For comparison, the latest primary-market quote was USD 62.47 on Nasdaq at 12:53 p.m. ET on October 20, 2026. The same quote showed a 52-week range of USD 58.80 to USD 90.87 and a market capitalization of USD 5.2 billion. PTC Therapeutics therefore remains 31.25 percent below its 52-week high on that basis.

October 29 is the next date

The next scheduled corporate event is the third-quarter report on October 29, 2026. PTC Therapeutics also completed the acquisition of the ST-920 Fabry disease gene therapy, a transaction listed on its investor-relations page alongside the second-quarter materials.

Stock price and reporting date

The October 29 reporting date places the next material company update within nine days. The second-quarter revenue increase of 101.50 percent and the USD 62.00 Truist target provide two quantified benchmarks for the upcoming release.

The stock was trading at EUR 55.60 at Lang & Schwarz on October 20, 2026 at 6:44 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of PTC Therapeutics stock.